March 13, 2008 – Abbott’s fully bioabsorbable drug-eluting stent for the treatment of coronary artery disease ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
Feature | Cristen C. Bolan
The Society for Cardiovascular Angiography and Interventions (SCAI) has partnered with the American College of ...
March 16, 2008
March 11, 2008 - Abbott announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm ...
March 10, 2008March 11, 2008 – Medtronic Inc. will feature its newly FDA-cleared Endeavor Zotarolimus-Eluting Coronary Stent System ...
March 10, 2008February 19, 2008 - A regimen of aspirin, clopidogrel and coumadin started at discharge decreased mortality and ...
February 18, 2008February 19, 2008 – A novel, fully bioabsorbable salicylate-based stent offers the potential to reduce adverse ...
February 18, 2008February 19, 2008 – The first CE certified Nobori Drug-Eluting Coronary Stent System was successfully implanted ...
February 18, 2008February 19, 2008 – Clinicians implanted the BioMatrix drug-eluting stent system into the first European patients ...
February 18, 2008February 18, 2008 – OrbusNeich’s Genous Bio-engineered R stent is feasible and safe for use in acute myocardial ...
February 17, 2008February 12, 2008 - Boston Scientific Corp. reported that a U.S. District Court jury in Marshall, TX, has reached a ...
February 11, 2008February 11, 2008 - Boston Scientific Corp. today announced that the first patient has been enrolled in its PROENCY ...
February 10, 2008February 11, 2008 - The first patient has enrolled in the PROENCY (PROMUS, Endeavor and Cypher) European registry ...
February 10, 2008February 5, 2008 – CV Therapeutics Inc. and Medlogics Device Corp. entered into an agreement under which Medlogics has ...
February 04, 2008January 31, 2008 - Stentys' bifurcated stent was successfully implanted recently into a 49-year-old male patient at the ...
January 31, 2008February 1, 2008 - Stentys' bifurcated stent was successfully implanted recently into a 49-year-old male patient ...
January 31, 2008© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now